Skip to main content

Table 4 Descriptive statistics of PK parameters for netupitant and palonosetron

From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

Netupitant AUC0-t(h  μg/L) Geo. Mean (Geo. SD) Cmax(μg/L) Geo. Mean (Geo. SD) tmax(h) Geo. Mean (Geo. SD)
NEPA200/0.5    
 Parent 4079 (1.712) 218.7 (1.833) 5.218 (1.589)
 M1 832.5 (1.719) 23.55 (1.594) 14.54 (1.668)
 M2 827.3 (1.722) 96.94 (1.842) 3.580 (1.342)
 M3 1348 (1.642) 46.73 (1.559) 10.70 (1.490)
NEPA600/1.5    
 Parent 12213 (1.925) 647.7 (2.205) 6.104 (1.474)
 M1 2007 (1.766) 53.71 (1.763) 17.82 (1.948)
 M2 2155 (1.908) 227.8 (2.024) 4.131 (1.208)
 M3 2981 (1.707) 101.5 (1.822) 11.51 (1.555)
Palonosetron AUC 0-t (hng/L) Geo. Mean (Geo. SD) C max (ng/L) Geo. Mean (Geo. SD) t max (h) Geo. Mean (Geo. SD)
NEPA200/0.5    
 Parent 22641 (1.241) 821.6 (1.277) 5.464 (1.437)
 M4 541.7 (2.916) 72.72 (1.379) 3.675 (1.764)
 M9 416.2 (2.158) 105.0 (1.383) 1.746 (1.348)
NEPA600/1.5    
 Parent 67918 (1.210) 2588 (1.239) 4.229 (1.693)
 M4 5571 (1.348) 231.0 (1.330) 3.388 (1.734)
 M9 3973 (1.468) 348.9 (1.313) 1.781 (1.535)
  1. AUC0-t, area under the plasma concentration-time curve data from administration until the last sampling point; Cmax, maximum plasma concentration; Geo., geometric; PK, pharmacokinetic; SD, standard deviation; tmax, time to Cmax.
  2. NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
  3. NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).